Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

NCT07315113 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Mutation Positive Non-small Cell Lung Cancer
EGFR Mutated Non-small Cell Lung Cancer Patients

Interventions

DRUG: NXP900
DRUG: Osimertinib

Sponsor

Nuvectis Pharma, Inc.